Journal of International Oncology››2018,Vol. 45››Issue (10): 593-598.doi:10.3760/cma.j.issn.1673-422X.2018.10.004
Previous ArticlesNext Articles
Liu He, Zhang Hong, Cong Jinchun, Cui Mingming, Liu Dingsheng, Chen Chunsheng
Received:
2018-03-12Online:
2018-10-08Published:
2018-12-21Contact:
Zhang Hong E-mail:haojiubujian1203@sina.cnLiu He, Zhang Hong, Cong Jinchun, Cui Mingming, Liu Dingsheng, Chen Chunsheng. Short-term safety assessment of raltitrexed intraperitoneal perfusion in patients with rectal cancer[J]. Journal of International Oncology, 2018, 45(10): 593-598.
[1] Wen B, Zhang L, Wang C, et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy[J]. Radiat Oncol, 2015, 10: 124. DOI: 10.1186/s13014-015-0425-5. [2] Heidary B, Phang TP, Raval MJ, et al. Transanal endoscopic microsurgery: a review[J]. Can J Surg, 2014, 57(2): 127-138. [3] Goodman MD, McPartland S, Detelich D, et al. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy[J]. J Gastrointest Oncol, 2016, 7(1): 4557. DOI: 10.3978/j.issn.20786891.2015.111. [4] Valle SJ, Alzahrani NA, Liauw W, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy[J]. Indian J Surg Oncol, 2016, 7(2): 152-159. DOI: 10.1007/s13193-016-0498-0. [5] Ba MC, Long H, Zhang XL, et al. Portsite metastases and chimney effect of Bultrasoundguided and laparoscopicallyassisted hyperthermic intraperitoneal perfusion chemotherapy[J]. Yonsei Med J, 2017, 58(3): 497-504. DOI: 10.3349/ymj.2017.58.3.497. [6] 韦金鸾. 恶性肿瘤腹腔灌注化疗药物的临床观察及护理[J]. 医药前沿, 2012, 21: 233234. [7] 池丽芬, 李民驹, 汤谷平. 顺铂腹腔热灌注化疗与其他用药方式药代动力学比较[J].实用肿瘤杂志, 2000, 15(3): 179-181. DOI: 10.3969/j.issn.1001-1692.2000.03.014. [8] UlrichPur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabinepretreated advanced pancreatic adenocarcinoma[J].Br J Cancer, 2003, 88(8): 1180-1184. DOI: 10.1038/sj.bjc.6600883. [9] Arends JJ, Sleeboom HP, Leys MB, et al. A phase Ⅱ study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma[J]. Br J Cancer, 2005, 92(3): 445-448. DOI: 10.1038/sj.bjc.6602368. [10] Avallone A, Delrio P, Guida C, et al. Biweekly oxaliplatin, raltitrexed, 5fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase Ⅰ-Ⅱ study[J]. Br J Cancer, 2006, 94(12): 1809-1815. DOI: 10.1038/sj.bjc.6603195. [11] Schmid KE, Kornek GV, Schull B, et al. Secondline treatment of advanced gastric cancer with oxaliplatin plus raltitrexed[J]. Onkologie, 2003, 26(3): 255-258. DOI: 10.1159/000071621. [12] Nguyen D, Emond C, Leclerc Y, et al. Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model[J]. Med Sci Monit, 2003, 9(1): BR37-42. [13] Bendavid Y, Leblond FA, Dubé P. A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat[J]. Med Sci Monit, 2005, 11(1): BR15. [14] Isozaki H, Okajima K, Fujii K. Histological evaluation of lymph node metastasis on serial sectioning in gastric cancer with radical lymphadenectomy[J]. Hepatogastroenterology, 1997, 44(16): 1133-1136. [15] Li W, Chang J, Wang S, et al. miRNA99b5p suppresses liver metastasis of colorectal cancer by downregulating mTOR[J]. Oncotarget, 2015, 6(27): 24448-24462. DOI: 10.18632/oncotarget.4423. [16] Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancerpathobiological pathways with clinical significance[J].World J Gastroenterol, 2014, 20(14): 37193737. DOI: 10.3748/wjg.v20.i14.3719. [17] Sag AA, Selcukbiricik F, Mandel NM. Evidencebased medical oncology and interventional radiology paradigms for liverdominant colorectal cancer metastases[J]. World J Gastroenterol, 2016, 22(11): 3127-3149. DOI: 10.3748/wjg.v22.i11.3127. [18] Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2012, 99(5):699-705. DOI: 10.1002/bjs.8679. [19] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(5): 663-671. DOI: 10.1200/JCO.2008.20.8397. [20] Van Cutsem E, Khne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-1417. DOI: 10.1056/NEJMoa0805019. [21] Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular selfdefense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev, 2012, 64(3): 706-721. DOI: 10.1124/pr.111.005637. [22] Poon MA, O′Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma[J]. J Clin Oncol, 1989, 7(10): 14071418. DOI: 10.1200/JCO.1989.7.10.1407. [23] 于飞洪, 巴明臣, 龙惠, 等. 雷替曲塞用于大肠癌患者腹腔热灌注化疗的思考与展望[J]. 中国医学工程, 2014, 22(5): 193-196. [24] 陈建林, 宋卫峰, 陈栋晖, 等. 雷替曲塞治疗晚期结直肠癌临床疗效的Meta分析[J]. 中国新药与临床杂志, 2010, 29(11): 853-858. [25] Liu Y, Wu W, Hong W, et al. Raltitrexedbased chemotherapy for advanced colorectal cancer[J]. Clin Res Hepatol Gastroenterol, 2014, 38(2): 219-225. DOI: 10.1016/j.clinre.2013.11.006. |
[1] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[2] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[3] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[4] | Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118. |
[5] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474. |
[6] | Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273. |
[7] | Zeng Liwu, Du Yuqiang, Zhang Peng, Tao Kaixiong.Progress in imaging evaluation of lateral lymph node metastasis in rectal cancer[J]. Journal of International Oncology, 2023, 50(4): 248-251. |
[8] | Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163. |
[9] | Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190. |
[10] | Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722. |
[11] | Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687. |
[12] | Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46. |
[13] | Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang.Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 555-559. |
[14] | He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang.Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563. |
[15] | Li Zhilei, Luo Jialin.Biological indexes for predicting sensitivity of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2022, 49(9): 564-567. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||